Annual EBITDA:
-$272.60M-$47.61M(-21.16%)Summary
- As of today, AXSM annual EBITDA is -$272.60 million, with the most recent change of -$47.61 million (-21.16%) on December 31, 2024.
- During the last 3 years, AXSM annual EBITDA has fallen by -$147.97 million (-118.73%).
- AXSM annual EBITDA is now -14720.27% below its all-time high of -$1.84 million, reached on December 31, 2013.
Performance
AXSM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$44.85M+$10.00M(+18.22%)Summary
- As of today, AXSM quarterly EBITDA is -$44.85 million, with the most recent change of +$10.00 million (+18.22%) on June 30, 2025.
- Over the past year, AXSM quarterly EBITDA has increased by +$31.20 million (+41.02%).
- AXSM quarterly EBITDA is now -2543.54% below its all-time high of -$1.70 million, reached on September 30, 2014.
Performance
AXSM Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$230.81M+$31.20M(+11.91%)Summary
- As of today, AXSM TTM EBITDA is -$230.81 million, with the most recent change of +$31.20 million (+11.91%) on June 30, 2025.
- Over the past year, AXSM TTM EBITDA has increased by +$67.60 million (+22.65%).
- AXSM TTM EBITDA is now -13503.41% below its all-time high of -$1.70 million, reached on September 30, 2014.
Performance
AXSM TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AXSM EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -21.2% | +41.0% | +22.6% |
| 3Y3 Years | -118.7% | -17.3% | -62.6% |
| 5Y5 Years | -306.5% | -152.4% | -137.8% |
AXSM EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -118.7% | at low | -851.9% | +53.5% | -62.6% | +22.7% |
| 5Y | 5-Year | -306.5% | at low | -851.9% | +53.5% | -142.1% | +22.7% |
| All-Time | All-Time | >-9999.0% | at low | -2543.5% | +53.5% | >-9999.0% | +22.7% |
AXSM EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$44.85M(+18.2%) | -$230.81M(+11.9%) |
| Mar 2025 | - | -$54.85M(+22.2%) | -$262.01M(+3.9%) |
| Dec 2024 | -$272.60M(-21.2%) | -$70.54M(-16.5%) | -$272.60M(+8.7%) |
| Sep 2024 | - | -$60.56M(+20.4%) | -$298.59M(-0.1%) |
| Jun 2024 | - | -$76.05M(-16.2%) | -$298.41M(-4.4%) |
| Mar 2024 | - | -$65.44M(+32.2%) | -$285.72M(-27.0%) |
| Dec 2023 | -$224.99M(-28.3%) | -$96.53M(-59.9%) | -$224.99M(-20.5%) |
| Sep 2023 | - | -$60.38M(+4.7%) | -$186.68M(-11.8%) |
| Jun 2023 | - | -$63.37M(-1244.8%) | -$167.04M(-17.7%) |
| Mar 2023 | - | -$4.71M(+91.9%) | -$141.93M(+19.0%) |
| Dec 2022 | -$175.40M(-40.7%) | -$58.23M(-42.9%) | -$175.19M(-17.1%) |
| Sep 2022 | - | -$40.73M(-6.5%) | -$149.57M(-5.4%) |
| Jun 2022 | - | -$38.26M(-0.7%) | -$141.95M(-5.7%) |
| Mar 2022 | - | -$37.98M(-16.5%) | -$134.26M(-8.4%) |
| Dec 2021 | -$124.63M(-24.3%) | -$32.61M(+1.5%) | -$123.86M(-4.2%) |
| Sep 2021 | - | -$33.11M(-8.3%) | -$118.88M(-9.9%) |
| Jun 2021 | - | -$30.57M(-10.9%) | -$108.14M(-13.4%) |
| Mar 2021 | - | -$27.57M(+0.2%) | -$95.34M(+4.9%) |
| Dec 2020 | -$100.26M(-49.5%) | -$27.63M(-23.5%) | -$100.26M(-3.3%) |
| Sep 2020 | - | -$22.37M(-25.9%) | -$97.05M(-3.8%) |
| Jun 2020 | - | -$17.77M(+45.3%) | -$93.48M(-4.9%) |
| Mar 2020 | - | -$32.49M(-33.0%) | -$89.14M(-32.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$67.07M(-125.1%) | -$24.42M(-29.9%) | -$67.07M(-29.0%) |
| Sep 2019 | - | -$18.80M(-39.9%) | -$51.98M(-26.2%) |
| Jun 2019 | - | -$13.44M(-29.1%) | -$41.18M(-15.3%) |
| Mar 2019 | - | -$10.41M(-11.5%) | -$35.72M(-19.9%) |
| Dec 2018 | -$29.79M(-8.1%) | -$9.34M(-16.7%) | -$29.79M(-8.2%) |
| Sep 2018 | - | -$8.00M(-0.3%) | -$27.53M(-7.5%) |
| Jun 2018 | - | -$7.98M(-78.1%) | -$25.61M(-5.1%) |
| Mar 2018 | - | -$4.48M(+36.7%) | -$24.38M(+11.6%) |
| Dec 2017 | -$27.56M(-1.9%) | -$7.08M(-16.4%) | -$27.56M(+0.2%) |
| Sep 2017 | - | -$6.08M(+9.8%) | -$27.62M(+3.9%) |
| Jun 2017 | - | -$6.74M(+12.0%) | -$28.75M(+0.3%) |
| Mar 2017 | - | -$7.66M(-7.3%) | -$28.83M(-6.6%) |
| Dec 2016 | -$27.05M(-135.8%) | -$7.14M(+0.8%) | -$27.05M(-6.7%) |
| Sep 2016 | - | -$7.20M(-5.5%) | -$25.34M(-25.7%) |
| Jun 2016 | - | -$6.82M(-16.0%) | -$20.16M(-30.7%) |
| Mar 2016 | - | -$5.88M(-8.3%) | -$15.42M(-33.5%) |
| Dec 2015 | -$11.47M(-109.0%) | -$5.43M(-168.5%) | -$11.55M(-43.2%) |
| Sep 2015 | - | -$2.02M(+2.9%) | -$8.07M(-4.2%) |
| Jun 2015 | - | -$2.08M(-3.6%) | -$7.74M(-36.8%) |
| Mar 2015 | - | -$2.01M(-3.2%) | -$5.66M(-55.2%) |
| Dec 2014 | -$5.49M(-198.4%) | -$1.95M(-14.8%) | -$3.65M(-114.8%) |
| Sep 2014 | - | -$1.70M | -$1.70M |
| Dec 2013 | -$1.84M | - | - |
FAQ
- What is Axsome Therapeutics, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Axsome Therapeutics, Inc.?
- What is Axsome Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Axsome Therapeutics, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Axsome Therapeutics, Inc.?
- What is Axsome Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Axsome Therapeutics, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Axsome Therapeutics, Inc.?
- What is Axsome Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Axsome Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of AXSM is -$272.60M
What is the all-time high annual EBITDA for Axsome Therapeutics, Inc.?
Axsome Therapeutics, Inc. all-time high annual EBITDA is -$1.84M
What is Axsome Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, AXSM annual EBITDA has changed by -$47.61M (-21.16%)
What is Axsome Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of AXSM is -$44.85M
What is the all-time high quarterly EBITDA for Axsome Therapeutics, Inc.?
Axsome Therapeutics, Inc. all-time high quarterly EBITDA is -$1.70M
What is Axsome Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, AXSM quarterly EBITDA has changed by +$31.20M (+41.02%)
What is Axsome Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of AXSM is -$230.81M
What is the all-time high TTM EBITDA for Axsome Therapeutics, Inc.?
Axsome Therapeutics, Inc. all-time high TTM EBITDA is -$1.70M
What is Axsome Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, AXSM TTM EBITDA has changed by +$67.60M (+22.65%)